Lorlatinib and local therapy for ALK-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study combines a daily targeted pill (lorlatinib) with a short course of radiation or surgery to treat ALK-positive lung cancer. The goal is to see if this two-step approach delays the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (stage IV) or returning non-small cell lung cancer (NSCLC).
- Your tumor has an ALK gene change (ALK-positive), shown by a special lab test.
- You have not been on an ALK-targeting pill before, OR you are just starting lorlatinib, OR you have been on alectinib, brigatinib, or ensartinib for less than 4 weeks.
- Your doctor believes you can get local treatment (radiation or surgery) for some tumor spots.
- You are in fairly good health (able to do daily activities without too much help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests lorlatinib, a pill that targets a specific genetic change in lung cancer cells (ALK-positive). It may help people with advanced lung cancer who have not yet had treatment for their advanced disease.
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
This study looks at whether giving a targeted therapy pill (lorlatinib) before surgery can help shrink ALK-positive lung cancer and improve outcomes. It also aims to understand why some tumors may not respond to this treatment.
This trial compares a newer targeted pill (lorlatinib) with standard chemoradiation (chemo plus radiation) for people with stage III ALK-positive lung adenocarcinoma. The goal is to see if lorlatinib alone works better than standard treatment and causes fewer side effects.
This study looks at how well and how safely the drug lorlatinib works in people with a certain type of advanced lung cancer (ALK-positive NSCLC) who have not had treatment for their advanced cancer yet. The goal is to see how effective it is in the real world.
This trial tests combining chemotherapy with lorlatinib for people with ALK-positive lung cancer that has spread outside the brain while on lorlatinib. The goal is to see if adding chemo can help control the cancer when it starts growing again.
Hear when a new Advanced Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.